drugset / Trial / NCT03192644
The Impact on Recurrence Risk of Adjuvant Transarterial Chemoinfusion (TAI) Versus Adjuvant Transarterial Chemoembolization (TACE) for Patients With Hepatocellular Carcinoma And Portal Vein Tumor Thrombosis (PVTT) After Hepatectomy : A Random, Controlled, Stage III Clinical Trial.
RandomizedParallel-groupOpen-labelTreatment
Summary
To compare the impact on recurrence risk of adjuvant TAI and adjuvant TACE for patients with HCC and PVTT after hepatectomy.
Timeline
- Start
- 2017-07-01
- Primary completion
- 2022-12-31
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cisplatin | Other / unclassified | — | Other |
| Comparator | Epirubicin | Small molecule | — | Other |
| Subject | Oxaliplatin | Small molecule | — | Other |
| Subject | fluorouracil | Small molecule | — | Other |
| Background | Calcium folinate | Unknown | — | Other |
| Comparator | lipiodol | Unknown | — | Other |